Replies to post #65262 on Biotech Values

[DewDiligence]

This is the initial Viread approval in the US for HBV.

http://biz.yahoo.com/bw/080811/20080811006425.html

GILD will now cease promotion of Hepsera for the simple reason that Viread works better.


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”